HealthQuill China
Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the Chinese company’s 12 potential medicines.
Drugs Health Pharma

GSK inks $500m deal with Jiangsu Hengrui for 12 potential medicines

HQ Team July 28, 2025: Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the.

Read More
The two hypothetical origins of the Covid-19 pandemic, namely the animal-to-human transmission and a laboratory leak, remain on the table as more information is needed to fully evaluate both, according to the World Health Organization.
Drugs Health Pharma

WHO says more information needed to track SARS-CoV-2 origins

HQ Team June 30, 2025: The two hypothetical origins of the Covid-19 pandemic, namely the animal-to-human transmission and a laboratory leak, remain on.

Read More
The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’ living cells to China and other “hostile countries” for the fear of genetic data misuse.
Drugs Health Pharma

US to review trials to stop genetic data misuse by China, ‘hostile’ nations

HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.

Read More
Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales threshold of its antifungal therapy in the Asia Pacific region, triggering a milestone payment.
Drugs Health Pharma

Sales surge triggers Pfizer’s $2.5 million milestone payment to Basilea

HQ Team June 5, 2025: Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales.

Read More
Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for a weight-loss drug candidate.
Drugs Health Pharma

Regeneron to pay China’s Hansoh $80m upfront for weight-loss drug

HQ Team June 2, 2025: Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for.

Read More
Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total of $170 million.
Drugs Health Pharma

Governments, philanthropic partners pledge $170 million to WHO

HQ Team May 21, 2025: Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total.

Read More
Pfizer Inc. has signed a licensing deal worth about $6 billion with China’s 3SBio to develop, manufacture and commercialise an experimental cancer drug.
Drugs Health Pharma

Pfizer signs $6 billion licensing deal with China’s 3SBio for cancer drug

HQ Team May 20, 2025: Pfizer Inc. has signed a licensing deal worth about $6 billion with China’s 3SBio to develop, manufacture and.

Read More
More than one in four cars sold worldwide is set to be electric this year, as the growth of electric vehicles is on course to exceed 40% in another five years, according to an International Energy Agency report.
Climate Health Research

Adaption of electric vehicles surges globally: One in four cars sold is an EV

HQ Team May 19, 2025: More than one in four cars sold worldwide is set to be electric this year, as the growth.

Read More
British-Swedish AstraZeneca Plc’s medicine used for adults with chronic obstructive pulmonary disease has been approved in the UK with a new propellant suited for the environment.
Climate Drugs Health

AstraZeneca’s environment-friendly inhaler gets UK regulator’s nod

HQ Team May 12, 2025: British-Swedish AstraZeneca Plc’s medicine used for adults with chronic obstructive pulmonary disease has been approved in the UK.

Read More
AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from the European Union.
Drugs Health Pharma

AstraZeneca’s lung cancer drug combination gets EU approval 

HQ Team April 4, 2025: AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from.

Read More